The transient protein expression market size is projected to reach US$ 1.32 billion by 2031 from US$ 836.68 million in 2023. The market is expected to register a CAGR of 5.9% during 2023-2031. Expanded application range of protein expression systems, including applications in the field of precision medicine, owing to the integration of artificial intelligence (AI) and automation technologies in protein expression workflows to enhance the efficiency, accuracy, and scalability of the overall process is likely to remain a key trend in the market.
The temporary protein expression process finds widespread application in the manufacturing of growth factors, cytokines, hormones, blood products, modified human proteins, and monoclonal antibodies. Moreover, the creation and use of effective bioprocessing techniques have become essential for the commercial synthesis of recombinant proteins with significant therapeutic value. Recent developments in the field of bioprocessing are being applied to provide efficient methods for generating recombinant proteins. Modern Quality by Design concepts, continuous upstream processing, continuous chromatography, integrated continuous bioprocessing, high-throughput devices for efficient bioprocess optimization, disposable systems, and process analytics technologies for higher yields of high-quality products are among the recent developments that propel the adoption of transient protein expression systems.
The use of plants has excellent potential for improving yields of proteins that can be administered for the prevention or treatment of human and animal diseases. The use of therapeutic proteins is likely to surge in the healthcare sector in the coming years due to the ongoing restructuring of regulatory frameworks and growing awareness about transient protein expression in plants. Maximum scale‐up possibility, low growth costs, complex protein production ability, low contamination (especially involving human pathogens) risks, and optimized growth conditions are among the key advantages associated with carrying out transient protein expression in plants. Moreover, plants are considered safer compared to other expression systems as they do not produce endotoxins and cause less harm to humans. Thus, plant-based expression systems for therapeutic protein expression are emerging as vital opportunities for the transient protein expression market growth during the forecast period.
Market Drivers of the Transient Protein Expression Market
Increasing Applications of Protein Expression Systems
Animal and plant cell-based transient protein expression systems have been in use for the last three decades. Significant advancements in proteomics in recent years have resulted in the availability of newer recombinant protein varieties. The practicality and reproducibility of transient protein expression in animal and plant cells encourage research and development activities to extend their applications in human cell lines. Many contract research and development organizations as well as biopharmaceutical companies, among others, have focused their efforts on incorporating transient protein expression into their production processes. This type of expression system allows them to use different genes to create recombinant proteins without relying on the development of stable cell lines.The temporary protein expression process finds widespread application in the manufacturing of growth factors, cytokines, hormones, blood products, modified human proteins, and monoclonal antibodies. Moreover, the creation and use of effective bioprocessing techniques have become essential for the commercial synthesis of recombinant proteins with significant therapeutic value. Recent developments in the field of bioprocessing are being applied to provide efficient methods for generating recombinant proteins. Modern Quality by Design concepts, continuous upstream processing, continuous chromatography, integrated continuous bioprocessing, high-throughput devices for efficient bioprocess optimization, disposable systems, and process analytics technologies for higher yields of high-quality products are among the recent developments that propel the adoption of transient protein expression systems.
Plant-Based Expression Systems for Therapeutic Protein Production in Emerging Countries to Create Market Opportunities
The use of microbial or mammalian cell-based expression systems has been a common practice in recombinant protein production processes; however, plant-based expression has been promoted as a cost-effective, scalable, safe, and sustainable alternative in recent years. Advancements in transient expression methods have resulted in a significantly shortened duration of protein synthesis and the improved yield of recombinant proteins in plant-based systems. A shift in consumer preference toward plant-based products compels pharmaceutical and biopharmaceutical companies to focus on plant-based synthesis of therapeutic proteins.The use of plants has excellent potential for improving yields of proteins that can be administered for the prevention or treatment of human and animal diseases. The use of therapeutic proteins is likely to surge in the healthcare sector in the coming years due to the ongoing restructuring of regulatory frameworks and growing awareness about transient protein expression in plants. Maximum scale‐up possibility, low growth costs, complex protein production ability, low contamination (especially involving human pathogens) risks, and optimized growth conditions are among the key advantages associated with carrying out transient protein expression in plants. Moreover, plants are considered safer compared to other expression systems as they do not produce endotoxins and cause less harm to humans. Thus, plant-based expression systems for therapeutic protein expression are emerging as vital opportunities for the transient protein expression market growth during the forecast period.
Transient Protein Expression Market: Segmental Overview
Key segments that contributed to the derivation of the transient protein expression market analysis are product type, application, and end user.- Based on product type, the transient protein expression market is segmented into instruments, reagents, expression vectors, and competent cells. The instruments segment held the largest market share in 2023.
- By application, the market is segmented into genomic research, gene therapy, bioproduction, cancer research, and drug development. The genomic research segment accounted for the largest share of the market in 2023.
- Based on end user, the transient protein expression market is segmented into pharmaceutical and biotechnology companies, academic and research institutes, and clinical research organizations. The pharmaceutical and biotechnology companies segment dominated the market in 2023.
Transient Protein Expression Market: Geographical Overview
The geographic scope of the transient protein expression market report is mainly divided into five regions: North America, Asia Pacific, Europe, the Middle East & Africa, and South & Central America. North America dominated the market in 2023. The North America transient protein expression market has been analyzed on the basis of the US, Canada, and Mexico. In terms of revenue, North America accounted for the largest market share in 2023. The US is the world's most important market for transient protein expression procedures and systems. The market growth in the country is attributed to extensive research and development activities in the biopharmaceuticals industry, a growing number of startups involved in protein expression, and the rising adoption of recombinant protein for therapeutic applications. In addition, the presence of various market leaders operating in the US contributes notably to the expansion of the transient protein expression market size.Reasons to Buy:
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the transient protein expression.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the global transient protein expression market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth global market trends and outlook coupled with the factors driving the transient protein expression, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.
Table of Contents
1. Introduction
2. Executive Summary
3. Research Methodology
4. Transient Protein Expression Market Landscape
5. Transient Protein Expression Market - Key Market Dynamics
6. Transient Protein Expression Market - Global Market Analysis
7. Transient Protein Expression Market Analysis - by Product Type
8. Transient Protein Expression Market Analysis - by Application
9. Transient Protein Expression Market Analysis - by End User
10. Transient Protein Expression Market - Geographical Analysis
11. Competitive Landscape
12. Industry Landscape
13. Company Profiles
14. Appendix
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Thermo Fisher Scientific
- Promega Corporation
- Merck KGAA
- Takara Bio Inc
- Qiagen
- Bio-Rad Laboratories, Inc.
- New England Biolabs
- Genscript Biotech Corporation
- Agilent, Lonza
- Mirus Bio LLC
- MaxCyte Inc
- DeRoyal Industries Inc
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 187 |
| Published | July 2024 |
| Forecast Period | 2023 - 2031 |
| Estimated Market Value in 2023 | 836.68 Million |
| Forecasted Market Value by 2031 | 1320.38 Million |
| Compound Annual Growth Rate | 5.9% |
| Regions Covered | Global |
